Pharvaris PHVS
NASDAQ PHVS
$36.13 +0.47 (+1.30%)
As of: Sep 4, 2026 · 12:51 PM EDT

Pharvaris (PHVS) Consolidated Net Income (2020 - 2026)

Pharvaris' (PHVS) quarterly Consolidated Net Income came in at -$45.3 million in Q1 2026, up 5.93% YoY from -$42.7 million in Q1 2025, and up 10.45% on a QoQ basis from -$50.5 million in Q4 2025.

Analysis

Pharvaris (PHVS) Consolidated Net Income (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Consolidated Net Income data on file, last reported at -$45.3 million in Q1 2026.

  • Quarterly Consolidated Net Income rose 5.93% year-over-year to -$45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.7 million (down 19.33% YoY) and the FY2025 annual result came in at -$194.0 million, down 37.29% from the prior year.
  • Consolidated Net Income improved to -$45.3 million in Q1 2026, from -$50.5 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$7.6 million in Q2 2022 to a low of -$51.0 million in Q2 2025.
  • A 5-year average of -$33.6 million and a median of -$34.5 million in 2024 frame the typical range for Consolidated Net Income.
  • Annual changes were most pronounced in 2022 — Consolidated Net Income surged 58.38% — and 2023, when it sank 210.34%.
  • Tracing PHVS's Consolidated Net Income over 5 years: stood at -$41.5 million in 2022, then grew by 10.56% to -$37.1 million in 2023, then gained by 6.95% to -$34.5 million in 2024, then slumped by 46.49% to -$50.5 million in 2025, then gained by 10.45% to -$45.3 million in 2026.
  • The last three Consolidated Net Income figures came in at -$45.3 million (Q1 2026), -$50.5 million (Q4 2025), and -$43.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Pharvaris 2.14 Bn 1.77 Bn 85,072.10 -54.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -54.21 Mn
Mar 31, 2026 -45.25 Mn
Dec 31, 2025 -50.53 Mn
Sep 30, 2025 -43.84 Mn
Jun 30, 2025 -51.02 Mn
Mar 31, 2025 -48.11 Mn
Dec 31, 2024 -34.50 Mn
Sep 30, 2024 -45.30 Mn
Jun 30, 2024 -31.86 Mn
Mar 31, 2024 -29.82 Mn
Dec 31, 2023 -33.63 Mn
Sep 30, 2023 -25.37 Mn
Jun 30, 2023 -23,640.02 Bn
Mar 31, 2023 -24.16 Mn
Dec 31, 2022 -39.37 Mn
Sep 30, 2022 -13.41 Mn
Jun 30, 2022 -7,617.57 Bn
Mar 31, 2022 -17.90 Mn
Dec 31, 2021 -14.16 Mn
Sep 30, 2021 -10.62 Mn